Company Information

  

Address: 830 WINTER ST  
City: WALTHAM 
State: MA 
Zip Code: 02451 
Telephone: (781)895-0600 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using our proprietary antibody-drug conjugate, or ADC, technology. An ADC with our technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a "payload" to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with two approved products and the number of agents in development more than doubling during the last five years. We have established a leadership position in ADCs. Our technology is deployed in Roche's Kadcyla┬« (ado-trastuzumab emtansine), the first ADC to demonstrate superiority over standard of care in a randomized pivotal trial, EMILIA, and gain FDA approval.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.08NAN/E
03/2017-1.50NAN/E
12/2016-1.81NAN/E
09/2016-1.79NAN/E
06/2016-1.67NAN/E
03/2016-1.56NAN/E
12/2015-1.44NAN/E
09/2015-0.84NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2013 Leverage 2013
Net Inc/Comm Equity-0.10Total Liab/Total Assets0.43
Net Inc/Total Assets-0.34Total Liab/Inv Cap0.47
Net Inc/Inv Cap-0.37Total Liab/Comm Equity0.13
Pretax Inc/Net Sales-2.05Interest Coverage RatioNA
Net Inc/Net Sales-2.05Curr Debt/EquityNA
Cash Flow/Net Sales-1.70LTD/EquityNA
SG&A/NetSales0.60Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover20.62Quick Ratio10.43
Inventory TurnoverNACurrent Ratio10.47
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.20Inv/Curr Assets0.00
Net Sales/PP&E3.30  

Income Statement (Millions)

  3/31/2014 12/31/2013 9/30/2013 6/30/2013
Total Revenues(Net Sales) 6.88 30.06 17.22 3.83
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.04 5.45 6.53 5.37
Operating Income -37.45 3.75 -11.34 -21.94
Interest Exp NA NA NA NA
Pretax Income -37.45 3.81 -11.23 -21.88
Other Income NA NA NA NA
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -37.45 3.81 -11.23 -21.88

Balance Sheet (Millions)

Assets 3/31/2014 12/31/2013 9/30/2013 6/30/2013
Cash & Short Term Investments 164.40 178.41 175.16 195.28
Receivables - Total 2.02 5.72 7.77 2.12
Inventories - Total 2.48 3.01 1.67 0.70
Total Current Assets 172.34 189.46 187.74 200.68
Net Property, Plant & Equipment 12.05 10.75 10.17 10.78
Total Assets 186.69 202.52 200.02 213.60
Liabilities        
Accounts Payable 18.36 14.13 13.30 16.70
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 21.20 17.63 16.54 19.17
Long-Term Debt NA NA NA NA
Total Liabilities 88.76 72.49 80.58 91.75
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.86 0.86 0.85 0.85
Retained Earnings -621.63 -584.18 -587.99 -576.77
Treasury Stock NA NA NA NA
Total Stockholders' Equity 97.93 130.04 119.44 121.85
Total Liabilities and Stockholders' Equity 186.69 202.52 200.02 213.60

Cash Flow Summary (Millions)

Categories 3/31/2014 12/31/2013 9/30/2013 6/30/2013
Net Cash Provided by Operating Activities -13.10 1.95 -23.58 -11.61
Net Cash Provided by Investing Activities -2.41 -1.73 -0.57 -1.34
Net Cash Provided by Financing Activities 1.50 3.03 4.03 1.81

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/200927.99-31.94--
06/201013.94-50.91--
06/201119.30-58.27-0.85
06/201216.36-73.32-0.95
06/201335.53-72.81-0.87
Growth Rates6.15----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1719891,51369.20




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.